As of 2025-05-15, the Intrinsic Value of Roivant Sciences Ltd (ROIV) is 50.51 USD. This ROIV valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 10.67 USD, the upside of Roivant Sciences Ltd is 373.40%.
The range of the Intrinsic Value is 42.13 - 63.95 USD
Based on its market price of 10.67 USD and our intrinsic valuation, Roivant Sciences Ltd (ROIV) is undervalued by 373.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 42.13 - 63.95 | 50.51 | 373.4% |
| DCF (Growth 10y) | 49.29 - 74.25 | 58.92 | 452.2% |
| DCF (EBITDA 5y) | 47.11 - 62.85 | 57.42 | 438.1% |
| DCF (EBITDA 10y) | 53.16 - 73.28 | 64.65 | 505.9% |
| Fair Value | -4.09 - -4.09 | -4.09 | -138.29% |
| P/E | 10.79 - 10.79 | 10.79 | 1.2% |
| EV/EBITDA | (13.99) - 128.50 | 54.48 | 410.6% |
| EPV | (13.10) - (19.36) | (16.23) | -252.1% |
| DDM - Stable | (1.06) - (2.17) | (1.61) | -115.1% |
| DDM - Multi | 28.49 - 46.73 | 35.52 | 232.9% |
| Market Cap (mil) | 7,613.58 |
| Beta | 0.86 |
| Outstanding shares (mil) | 713.55 |
| Enterprise Value (mil) | 5,622.90 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.28% |
| Cost of Debt | 5.50% |
| WACC | 9.07% |